https://www.selleckchem.com/pr....oducts/liraglutide.h
Background Complete response (CR) and very good partial response (VGPR) are targeted with pre-ASCT induction regimens in patients by diagnosed multiple myeloma (MM), who are candidates for ASCT. In this study, it was aimed to compare the response and survival evaluations of cases who underwent induction treatment by vincristine-doxorubicin-dexamethasone (VAD) protocol versus bortezomib containing regimens. Materials and Methods The data of 96 ASCT eligible patients, retrospectively analyzed. P value 0.05 was considered statistic
Like
Comment
Share
